{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:49:46Z","timestamp":1790419786147,"version":"4.1.0"},"reference-count":49,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by increased platelet counts. ET has an incidence of 0.6 to 2.5 per 100,000 per year in Europe and North America. The disease is characterized by an increased thromboembolic risk, possibly caused by increased platelet counts. Furthermore, increased platelet function and\/or increased platelet turnover may play a role. We aimed to explore: (1) whether platelet function and platelet turnover are increased in ET patients compared with healthy controls, and (2) whether these parameters are associated with increased thromboembolic risk and, therefore, may support decision-making on treatment in ET patients. We performed a systematic literature search on March 20, 2020 in Embase and PubMed following the Preferred Reporting Items for Systematic and Meta-Analysis (PRISMA) guidelines. In total, 1,923 articles were identified, 38 of which were included according to prespecified inclusion and exclusion criteria. Among the 38 studies, platelet activation (CD36 and CD62P) was investigated in 18 studies and was found to be increased in 12 of these. Platelet aggregation was investigated in 21 studies and was reported to be reduced in 20 of them. Platelet turnover (immature platelet count and mean platelet volume) was investigated in five studies with inconclusive results. No parameters were reported to predict the risk of thromboembolic events. In conclusion, platelet activation was increased in ET patients, but platelet aggregation was reduced. Future studies exploring markers of thromboembolic risk in ET patients are warranted.<\/jats:p>","DOI":"10.1055\/s-0040-1718873","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T23:50:27Z","timestamp":1612223427000},"page":"090-101","source":"Crossref","is-referenced-by-count":16,"title":["Platelet Function and Turnover in Essential Thrombocythemia: A Systematic Review"],"prefix":"10.1055","volume":"47","author":[{"given":"Joachim","family":"Kvernberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Beier","family":"Ommen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"},{"name":"Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mette","family":"Hvas","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/cyto.b.21642","article-title":"Platelet characteristics in patients with essential thrombocytosis","volume":"94","author":"O H Pedersen","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO;2-3","article-title":"Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients","volume":"67","author":"M Colombi","year":"1991","journal-title":"Cancer"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3109\/09537104.2012.731112","article-title":"Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment","volume":"24","author":"G Rem\u00e9nyi","year":"2013","journal-title":"Platelets"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11739-009-0284-x","article-title":"Essential thrombocythemia: past and present","volume":"4","author":"F Fabris","year":"2009","journal-title":"Intern Emerg Med"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2\u2009V617F allele burden","volume":"84","author":"E Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0609.2004.00219.x","article-title":"The predictive value of megakaryocytic and erythroid colony formation and platelet function tests on the risk of thromboembolic and bleeding complications in essential thrombocythaemia","volume":"72","author":"R Niittyvuopio","year":"2004","journal-title":"Eur J Haematol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ajh.1145","article-title":"Relationships between thrombohemorrhagic complications and platelet function in patients with essential thrombocythaemia","volume":"68","author":"A Raszeja-Specht","year":"2001","journal-title":"Am J Hematol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12288-016-0685-8","article-title":"The impact of mean platelet volume (MPV) and JAK-2 mutation on thrombosis in chronic myeloproliferative diseases","volume":"33","author":"M Ayer","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood.V91.4.1288","article-title":"Correlation of thrombosis with increased platelet turnover in thrombocytosis","volume":"91","author":"H M Rinder","year":"1998","journal-title":"Blood"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12185-014-1673-0","article-title":"Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR\/ABL-negative myeloproliferative neoplasms","volume":"100","author":"J Kissova","year":"2014","journal-title":"Int J Hematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.12659\/AJCR.904148","article-title":"Recurrent cardiovascular events despite antiplatelet therapy in a patient with polycythemia vera and accelerated platelet turnover","volume":"18","author":"O H Pedersen","year":"2017","journal-title":"Am J Case Rep"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/09537104.2019.1636019","article-title":"Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia","volume":"31","author":"J QD Tran","year":"2020","journal-title":"Platelets"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00320951","article-title":"The possible value of platelet aggregation studies in patients with increased platelet number","volume":"43","author":"F Fabris","year":"1981","journal-title":"Blut"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/10245332.1999.11746464","article-title":"Markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera","volume":"4","author":"C Musolino","year":"2000","journal-title":"Hematology"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000111776","article-title":"Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia","volume":"118","author":"R R Cacciola","year":"2007","journal-title":"Acta Haematol"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0038-1657135","article-title":"Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders","volume":"47","author":"F I Pareti","year":"1982","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/107602960200800104","article-title":"Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation","volume":"8","author":"K Presseizen","year":"2002","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2141.1995.tb05357.x","article-title":"Increased platelet CD36 constitutes a common marker in myeloproliferative disorders","volume":"91","author":"V Thibert","year":"1995","journal-title":"Br J Haematol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12185-013-1475-9","article-title":"JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients","volume":"99","author":"M Coucelo","year":"2014","journal-title":"Int J Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0049-3848(02)00354-7","article-title":"Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes","volume":"108","author":"T Villmow","year":"2002","journal-title":"Thromb Res"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0049-3848(91)90103-4","article-title":"Circulating activated platelets in myeloproliferative disorders","volume":"61","author":"A Wehmeier","year":"1991","journal-title":"Thromb Res"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00001721-200404000-00006","article-title":"Assessment of platelet activation in myeloproliferative disorders with complementary techniques","volume":"15","author":"E Bermejo","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1600-0609.1991.tb01855.x","article-title":"An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications","volume":"47","author":"J Zahavi","year":"1991","journal-title":"Eur J Haematol"},{"issue":"05","key":"ref25","first-page":"251","article-title":"Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease","volume":"19","author":"A Wehmeier","year":"1989","journal-title":"Haemostasis"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0609.1989.tb00312.x","article-title":"Platelet behavior in essential thrombocythemia: a study of 31 cases","volume":"43","author":"M Bazzan","year":"1989","journal-title":"Eur J Haematol"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.2830490406","article-title":"Platelet von Willebrand factor abnormalities in myeloproliferative syndromes","volume":"49","author":"G Castaman","year":"1995","journal-title":"Am J Hematol"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia","volume":"74","author":"B Rocca","year":"1995","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0049-3848(87)90443-9","article-title":"Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders","volume":"48","author":"S Meschengieser","year":"1987","journal-title":"Thromb Res"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.thromres.2009.06.030","article-title":"The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis","volume":"125","author":"A E Tsantes","year":"2010","journal-title":"Thromb Res"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.thromres.2005.09.008","article-title":"Lactate production by thrombin-activated platelets of patients with primary thrombocythemia","volume":"118","author":"J M Cesar","year":"2006","journal-title":"Thromb Res"},{"issue":"01","key":"ref32","first-page":"64","article-title":"Platelet function and its clinical significance in the myeloproliferative disorders","volume":"8","author":"A Zeidman","year":"2005","journal-title":"HAEMA"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0049-3848(95)00064-X","article-title":"Arachidonic acid metabolism in platelets of patients with essential thrombocythaemia","volume":"78","author":"O Mayordomo","year":"1995","journal-title":"Thromb Res"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF01727421","article-title":"Familial essential thrombocythemia: clinical characteristics of 11 cases in one family","volume":"68","author":"R J Schlemper","year":"1994","journal-title":"Ann Hematol"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0025-6196(12)60486-8","article-title":"Essential thrombocythemia in young adults","volume":"66","author":"K J McIntyre","year":"1991","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/1097-0142(19880615)61:12<2487::AID-CNCR2820611217>3.0.CO;2-T","article-title":"Essential thrombocythemia. clinical characteristics and course of 61 cases","volume":"61","author":"R Hehlmann","year":"1988","journal-title":"Cancer"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO;2-Y","article-title":"Essential thrombocythemias. Clinical evolutionary and biological data","volume":"58","author":"S Bellucci","year":"1986","journal-title":"Cancer"},{"issue":"04","key":"ref38","first-page":"469","article-title":"Platelet function after busulphan in chronic myeloproliferative disorders","volume":"68","author":"T Barbui","year":"1983","journal-title":"Haematologica"},{"issue":"09","key":"ref39","first-page":"578","article-title":"Primary thrombocythemia in the young patient","volume":"53","author":"H C Hoagland","year":"1978","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0002-8703(78)90123-0","article-title":"Arterial thrombosis in essential thrombocythemia","volume":"96","author":"S Hussain","year":"1978","journal-title":"Am Heart J"},{"issue":"07","key":"ref41","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.31557\/APJCP.2019.20.7.2079","article-title":"Platelet function tests and inflammatory markers for the differentiation of primary thrombocytosis and secondary thrombocytosis","volume":"20","author":"P Kanya","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0002-9343(90)90491-U","article-title":"Hemostatic complications in young patients with essential thrombocythemia","volume":"88","author":"A J Mitus","year":"1990","journal-title":"Am J Med"},{"issue":"26","key":"ref43","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"T Barbui","year":"2012","journal-title":"Blood"},{"issue":"16","key":"ref44","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"A Tefferi","year":"2014","journal-title":"Blood"},{"issue":"25","key":"ref45","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"T Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"A Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0036-1571308","article-title":"Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes","volume":"42","author":"S Neergaard-Petersen","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jth.12967","article-title":"Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count","volume":"13","author":"S Lancellotti","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"A Rottenstreich","year":"2017","journal-title":"Eur J Intern Med"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1718873.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T23:54:26Z","timestamp":1612223666000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1718873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":49,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,2,1]]},"published-print":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1718873","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}